Celltrion Pharm
Key metrics
Earnings
| Revenue, Q3 2026 | ₩161.9bn |
|---|---|
| Revenue QoQ | +5.6% |
| Revenue YoY | +17.2% |
| Operating income, Q3 2026 | ₩23.9bn |
| Operating income QoQ | +23.8% |
| Operating income YoY | +48.4% |
Share buybacks
| Buyback decided, last 3 months | ₩0 |
|---|---|
| Buyback decided, last 3 months, % of shares | 0.0% |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | 0.0% |
| Treasury shares cancelled, last 3 months | ₩0 |
| Treasury shares cancelled (number), last 3 months | 0 shares |
| Treasury shares cancelled, last 3 months, % of shares | 0.0% |
| Buyback decided, last 12 months | ₩0 |
| Buyback decided, last 12 months, % of shares | 0.0% |
| Shares acquired, last 12 months | ₩0 |
| Shares acquired, last 12 months, % of shares | 0.0% |
| Treasury shares cancelled, last 12 months | ₩14.0bn |
| Treasury shares cancelled (number), last 12 months | 149,993 shares |
| Treasury shares cancelled, last 12 months, % of shares | 0.3% |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩0 |
|---|---|
| Rights offering new shares, last 12 months | 0 shares |
| Potential new shares, last 12 months | 0 shares |
| Potential new shares, % of shares | 0.0% |
| Conversion price adjustments, last 12 months | 0 |
Supply contracts
| Supply contracts, last 12 months | ₩0 |
|---|---|
| Supply contracts vs prior-year revenue | 0.0% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 3 |
|---|---|
| DART filings, previous 3 months | 6 |
Insider transactions
| Open-market buys, last 12 months (shares) | 0 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩0 |
| Open-market sells, last 12 months (shares) | 0 shares |
| Open-market sells, last 12 months (amount) | ₩0 |
| Net open-market buying, last 12 months (shares) | 0 shares |
| Insiders who bought, last 12 months | 0 |
Insider transactions (last 12 months)
Open-market buys: 0 shares (₩0). Open-market sells: 0 shares (₩0). Net open-market buying: 0 shares. Insiders who bought: 0.
| Trade date | Insider (role) | Type | Shares | Price | Amount | |
|---|---|---|---|---|---|---|
| Mar 24, 2026 | Choi Seung-jae (Non-registered officer) | Other | +105 shares | ₩500 | ₩52,500 | |
| Mar 24, 2026 | Lee Eon-hyeong (Non-registered officer) | Other | +191 shares | ₩500 | ₩95,500 | |
| Mar 24, 2026 | Yang Ji-seok (Non-registered officer) | Other | +114 shares | ₩500 | ₩57,000 | |
| Mar 24, 2026 | Choi Deok-gyu (Non-registered officer) | Other | +165 shares | ₩500 | ₩82,500 | |
| Mar 24, 2026 | Yoo Yeong-ho (Registered director) | Other | +117 shares | ₩500 | ₩58,500 | |
| Mar 24, 2026 | Kim Ju-beom (Non-registered officer) | Other | +45 shares | ₩500 | ₩22,500 | |
| Mar 24, 2026 | Kim Seung-hwan (Non-registered officer) | Other | +8 shares | ₩500 | ₩4,000 | |
| Mar 24, 2026 | Celltrion, Inc. (10%+ shareholder) | Other | +478,749 shares | — | — | |
| Feb 14, 2026 | Woo Yeong-je (Non-registered officer) | Other (Retirement as officer) | -6,066 shares | — | — | |
| Jan 29, 2026 | Kim Ju-beom (Non-registered officer) | Other (Stock option exercise) | +762 shares | ₩48,002 | ₩37m |
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩536.4bn | ₩56.1bn |
| 2024 | ₩477.8bn | ₩37.2bn |
| 2023 | ₩388.8bn | ₩36.1bn |
Filing timeline
-
Celltrion Pharm treasury share disposal of 553 shares for stock option exercise
Celltrion Pharm Inc. filed a treasury share disposal of 553 shares with a planned amount of ₩9m, dated Nov 13, 2026. The disposal is made for the exercise of stock options, through delivery of treasury shares as compensation for the difference.